In this special podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks with Prof. Thomas Powles (GB) about the positive results of the EV-302/KEYNOTE-A39 trial that were announced at ESMO 2023. 

Prof. Powles shares details on the rationale and design of the EV-302/KEYNOTE-A39 study: an open-label, randomised, controlled, phase 3 study evaluating enfortumab vedotin in combination with pembrolizumab (EV+P) versus chemotherapy in patients with previously untreated locally advanced metastatic urothelial carcinoma (la/mUC).

The dual endpoints of this trial are overall survival (OS) and progression-free survival (PFS) per RECIST (response evaluation criteria in solid tumours) v 1.1 by blinded independent central review (BICR).

Prof. Powles: "The topline results from the EV-302/KEYNOTE-A39 trial are encouraging for patients with advanced-stage urothelial cancer, which is aggressive and associated with devastating outcomes."

For more details on this study, you can read the abstract on the UROONCO Bladder Cancer educational platform.